Analyst Price Targets — NPCE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 11:04 am | — | H.C. Wainwright | $19.00 | $16.23 | TheFly | NeuroPace price target raised to $19 from $18 at H.C. Wainwright |
| December 16, 2025 12:49 pm | — | UBS | $22.00 | $15.93 | TheFly | NeuroPace price target raised to $22 from $18 at UBS |
| December 9, 2025 12:58 pm | Priya Sachdeva | UBS | $18.00 | $16.37 | StreetInsider | UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results |
| November 5, 2025 11:20 am | Mike Kratky | Leerink Partners | $19.00 | $9.40 | StreetInsider | NeuroPace Inc (NPCE) PT Raised to $19 at Leerink Partners |
| November 5, 2025 11:04 am | Ross Osborn | Cantor Fitzgerald | $16.00 | $9.40 | StreetInsider | Cantor Fitzgerald Says NeuroPace Inc (NPCE) Remains a Top Pick |
| August 14, 2024 6:30 am | Vik Chopra | Wells Fargo | $15.00 | $7.28 | TheFly | NeuroPace price target lowered to $15 from $20 at Wells Fargo |
| May 23, 2024 8:44 am | Frank Takkinen | Lake Street | $20.00 | $7.99 | TheFly | NeuroPace post Q1 move 'overdone,' says Lake Street |
| March 14, 2024 5:08 am | Larry Biegelsen | Wells Fargo | $20.00 | $13.63 | StreetInsider | Wells Fargo Upgrades NeuroPace Inc (NPCE) to Overweight |
| November 10, 2023 2:34 pm | Ross Osborn | Cantor Fitzgerald | $11.00 | $7.85 | Benzinga | Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position |
| July 15, 2022 11:42 am | — | Morgan Stanley | $5.50 | $5.74 | Benzinga | Morgan Stanley Maintains Underweight on NeuroPace, Lowers Price Target to $5.5 |
Latest News for NPCE
NeuroPace (NPCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern…
Shares of NeuroPace, Inc. (NASDAQ: NPCE - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $26.6 million, an increase of 24% over the fourth quarter of 2024. RNS revenue is expected to be approximately $22.4 million,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NPCE.
U.S. House Trading
No House trades found for NPCE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.